Skip to Main Content

Author Details

Brian J Davis
Mayo Clinic
1997
149
40
PMIDPaper TitleJournal TitlePublished Year
37899635Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.Prostate2024
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
37391235Proton Beam Therapy Training, Experience, and Assessment: Ready for Prime Time.Pract Radiat Oncol2023
37059334Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study.Radiother Oncol2023
36427645Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys2023
34775126In Regard to Dover et al.Pract Radiat Oncol2022
35789497A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.Prostate2022
35588224ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer.Am J Clin Oncol2022
36845611Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy.Adv Radiat Oncol2022
36070558Cost effectiveness of treatment strategies for high risk prostate cancer.Cancer2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
32861817NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.Int J Radiat Oncol Biol Phys2021
33742974Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT).Curr Opin Urol2021
33545689NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.J Natl Compr Canc Netw2021
33539968A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.Int J Radiat Oncol Biol Phys2021
33636378Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.Pract Radiat Oncol2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34722810Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity.Int J Part Ther2021
34509378Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement.Brachytherapy2021
34593526Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in <sup>11</sup>C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
34023327The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer.Radiother Oncol2021
33309278A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).Eur Urol2021
33268854Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.Prostate Cancer Prostatic Dis2021
33127490Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer.Int J Radiat Oncol Biol Phys2021
33063697<sup>11</sup>C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen ⿤0.1 ng/ml.J Cancer Res Ther2021
32109600Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center.Pract Radiat Oncol2020
31758947c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.Neuropharmacology2020
33090219Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.JAMA Oncol2020
32931662Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.Cancer Med2020
30293836Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.Brachytherapy2019
31673659<sup>11</sup>C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities.Adv Radiat Oncol2019
30205124Prospective Immunophenotyping of CD8<sup>+</sup> T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.Int J Radiat Oncol Biol Phys2019
31177044Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.Radiother Oncol2019
31011676Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.Adv Radiat Oncol2019
30853392Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds.Brachytherapy2019
31085758Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.J Natl Compr Canc Netw2019
31085757Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2019
30967226The American Board of Radiology Initial Certification in Radiation Oncology: Moving Forward Through Collaboration.Int J Radiat Oncol Biol Phys2019
30902522Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.Clin Genitourin Cancer2019
28916273Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using <sup>11</sup>C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging.J Urol2018
32775476Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis.Bladder (San Franc)2018
30050795Low dose rate prostate brachytherapy.Transl Androl Urol2018
30212298The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.J Clin Oncol2018
30037499Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group.Radiother Oncol2018
30706014Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.Adv Radiat Oncol2018
29724417ACR Appropriateness Criteria<sup>®</sup> Post-treatment Follow-up Prostate Cancer.J Am Coll Radiol2018
29037965Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.Pract Radiat Oncol2018
27527896Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil.Pract Radiat Oncol2017
  • 1 - 50 of 149

Recommended Authors

Audrey Dang
Tulane University School of Medicine
Career Start Year 2018
Number of shared co-authors 26
Niluja Thiruthaneeswaran
The University of Sydney, Westmead Hospital
Career Start Year 2014
Number of shared co-authors 6
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 23
Kiri A Sandler
Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 38
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 7
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 19
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 6
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 12
Nima Aghdam
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 26
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Career Start Year 2005
Number of shared co-authors 28
Baris Turkbey
National Cancer Institute, National Institutes of Health
Career Start Year 2005
Number of shared co-authors 12
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 15
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 3
Tim Dudderidge
University Hospital Southampton NHS Foundation Trust
Career Start Year 2002
Number of shared co-authors 1
Tobias Maurer
Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf
Career Start Year 2002
Number of shared co-authors 26
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 3
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 47
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 9
Constantine A Mantz
University of Chicago
Career Start Year 1997
Number of shared co-authors 29
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 27
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 10
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 29
Alan Thompson
The Royal Marsden NHS Foundation Trust
Career Start Year 1996
Number of shared co-authors 1
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 34
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 9
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 22
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 49
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Career Start Year 1986
Number of shared co-authors 21
Joseph L Chin
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 11
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 46

Collaborators

Thomas M Pisansky
Mayo Clinic
Co-authored papers 42
Bradley J Stish
Mayo Clinic
Co-authored papers 30
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 27
Richard Choo
Mayo Clinic
Co-authored papers 25
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 14
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 13
Gregory S Merrick
Urologic Research Institute, Ohio University School of Medicine
Co-authored papers 13
Anthony V D'Amico
Duke University Medical Center
Co-authored papers 13
Richard G Stock
Icahn School of Medicine at Mount Sinai
Co-authored papers 12
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 11
Neha Vapiwala
Abramson Cancer Center, University of Pennsylvania
Co-authored papers 10
Mack Roach
University of California San Francisco
Co-authored papers 10
C Richard Choo
Mayo Clinic
Co-authored papers 10
Jay P Ciezki
Cleveland Clinic
Co-authored papers 8
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Co-authored papers 8
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 7
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 7
Daniel J Krauss
William Beaumont School of Medicine
Co-authored papers 7
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 7
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 7
Robert T Dess
University of Michigan ann arbor
Co-authored papers 7
Amar U Kishan
University of California los angeles
Co-authored papers 7
Michael L Steinberg
University of California los angeles
Co-authored papers 7
David Jeffrey Demanes
University of California los angeles
Co-authored papers 7
Chandana A Reddy
Cleveland Clinic
Co-authored papers 6
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 6
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 6
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 6
Curtiland Deville
Johns Hopkins University
Co-authored papers 6
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Release 1.2